PXMD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms...

Stats
Today's Volume	1.10M
Average Volume	1.82M
Market Cap	4.33M
EPS	$0 ( 2023-11-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.0890 (9.32%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-27	Coelho John F	Sell	12	Common Stock
2023-11-27	Weisman Howard J.	Sell	162	Common Stock
2023-11-27	Derby Michael	Sell	185	Common Stock
2023-11-27	Larochelle Karen	Sell	35	Common Stock
2023-11-27	Rome Zachary	Sell	359	Common Stock

INSIDER POWER
26.37
Last 86 transactions
Buy: 1 048 583 \| Sell: 546 940

Volume Correlation

Long: 0.94 (very strong)

Short: 0.98 (very strong)

Signal:(54) Expect same movement, but be aware

PaxMedica, Inc. Common Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PaxMedica, Inc. Common Correlation - Currency/Commodity

0.72
( moderate )

0.78
( moderate )

0.00
( neutral )

0.92
( very strong )

PaxMedica, Inc. Common Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.17

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-5.19

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-4.04

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-4.89

PaxMedica, Inc. Common

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.